Back to Search Start Over

Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.

Authors :
Cavin S
Gkasti A
Faget J
Hao Y
Letovanec I
Reichenbach M
Gonzalez M
Krueger T
Dyson PJ
Meylan E
Perentes JY
Source :
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery [Eur J Cardiothorac Surg] 2020 Oct 01; Vol. 58 (4), pp. 783-791.
Publication Year :
2020

Abstract

Objectives: Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we have demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM. Here, we hypothesized that L-PDT vascular modulation could favour immune cell extravasation in MPM and improve tumour control in combination with immune checkpoint inhibitors.<br />Methods: First, we assessed the impact of L-PDT on vascular endothelial E-selectin expression, a key molecule for immune cell extravasation, in vitro and in a syngeneic murine model of MPM. Second, we characterized the tumour immune cell infiltrate by 15-colour flow cytometry analysis 2 and 7 days after L-PDT treatment of the murine MPM model. Third, we determined how L-PDT combined with immune checkpoint inhibitor anti-CTLA4 affected tumour growth in a murine MPM model.<br />Results: L-PDT significantly enhanced E-selectin expression by endothelial cells in vitro and in vivo. This correlated with increased CD8+ T cells and activated antigen-presenting cells (CD11b+ dendritic cells and macrophages) infiltration in MPM. Also, compared to anti-CTLA4 that only affects tumour growth, the combination of L-PDT with anti-CTLA4 caused complete MPM regression in 37.5% of animals.<br />Conclusions: L-PDT enhances E-selectin expression in the MPM endothelium, which favours immune infiltration of tumours. The combination of L-PDT with immune checkpoint inhibitor anti-CTLA4 allows best tumour control and regression.<br /> (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)

Details

Language :
English
ISSN :
1873-734X
Volume :
58
Issue :
4
Database :
MEDLINE
Journal :
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Publication Type :
Academic Journal
Accession number :
32372095
Full Text :
https://doi.org/10.1093/ejcts/ezaa145